Kapadi Spain
Kapadi Spain is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, two-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria (ABIGAIL).
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy
Sponsor Fundacion Oncosur
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available6 trial-level findings · Read insights
- Phase II recruited 145 patients versus the planned 160 patients.
- All 145 full-analysis-set patients were enrolled at 13 sites in Spain, with no enrollment from other EU or third countries.
- There were major protocol deviations in 40 patients.
- Protocol version 3.0 modified the inclusion criteria on 2 August 2021.
- The statistical analysis plan changed overall-survival landmark reporting from 12, 18, and 24 months to 6 and 12 months.
- No global study halts, temporary suspensions, or restarts occurred.
These findings describe the trial, not the service provider’s performance or responsibility.
A Prospective, randomized, single blind, multicenter Phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in liver transplantation
Sponsor Dr. Franz Koehler Chemie GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Sponsor Biofabri S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Kapadi Spain?
The 2026-10-09 snapshot links Kapadi Spain to 6 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Safety reporting & pharmacovigilance, Data management, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Kapadi Spain?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Hepatology, Respiratory, Surgery and Perioperative Care. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Kapadi Spain conducted?
The linked trials record locations in 5 countries, including Spain, Italy, Germany, Hungary, Portugal. These are trial locations, not confirmed office locations or countries where Kapadi Spain delivered services.
What can this page tell me about Kapadi Spain's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Kapadi Spain. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Kapadi Spain S.L.